BASF Expands Innovation Campus Asia Pacific in Shanghai
BASF, the world’s leading chemical company, today broke ground on the second phase of its Innovation Campus Asia Pacific at its Pudong site in Shanghai, China. The €90 million expansion consists of an additional regional R&D building and auxiliary facilities and it will be completed by the end of 2015.
“By 2020, around 25% of BASF’s R&D employees will be located in Asia Pacific. The expansion reinforces BASF’s commitment to globalising its R&D activities and capturing growth opportunities in China and Asia Pacific,” said Dr Andreas Kreimeyer, member of the Board of Executive Directors of BASF SE and Research Executive Director.
The Innovation Campus is BASF’s most important R&D center in the region and is expected to become one of its largest R&D sites outside of Germany. With the expansion, BASF’s regional research capabilities will be further strengthened, focusing primarily on advanced materials and systems, as well as adding new areas such as formulations and chemical process and engineering serving growth industries such as automotive, construction, health and nutrition, and home and personal care.
“The Innovation Campus Asia Pacific in Shanghai has proven to be an effective platform that not only responds quickly to market needs in China and Asia Pacific, but also connects BASF with the science community in Asia Pacific. The enthusiasm for innovation among our colleagues, customers and partners is the cornerstone of solutions for a sustainable future in the region,” said Dr Martin Brudermüller, Vice Chairman of the Board of Executive Directors of BASF SE, responsible for Asia Pacific.
In Asia, in addition to the Innovation Campus in Shanghai, BASF also has R&D centers in Japan, Singapore and Korea. An Innovation Campus in India is also planned. BASF increased global spending on R&t to €1.8 billion in 2013 (2012: €1.7 billion), with around 10,650 scientists and researchers working in 3000 research projects. With 1300 patents filed last year and about 151,000 registrations and intellectual property rights worldwide, BASF is at the top of the global Patent Asset Index for the fifth time in succession.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News From Pharma to Table? Direct-to-consumer pharma sales and price cuts ramp up in US
The pharmaceutical industry is witnessing a seismic shift as major companies embrace direct-to-consumer sales models and announce significant price reductions across the United States, responding to mounting pressure from the Trump administration to ta... -
News A Day in the Life of a Director of Business Development
In this Day in the Life of interview, Thomas Hauser, Director of Business Development at Tjoapack. Thomas has spent nearly 30 years in the pharmaceutical industry and describes how he still finds curiosity and excitement in the bigger picture of global... -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective.